Specifically, continuous research on immunotherapeutic agents, including PD-1/PD-L1, TMB, ctDNA, microsatellite stability, DNA mismatch repair, neutrophil/lymphocyte ratio, cytokines, and cellular peripheral immune response has shown promising results, especially in patients with HCC resistant to classical chemotherapy [131,132,133]. The gene discussed is CD274; the disease is hepatocellular carcinoma.